相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Formulation and Evaluation of Lipidized Imiquimod as an Effective Adjuvant
Wenzhu Yin et al.
ACS INFECTIOUS DISEASES (2023)
SARS-CoV-2 subunit vaccine adjuvants and their signaling pathways
Daniel Mekonnen et al.
EXPERT REVIEW OF VACCINES (2022)
The global epidemic of SARS-CoV-2 variants and their mutational immune escape
Dandan Tian et al.
JOURNAL OF MEDICAL VIROLOGY (2022)
Considerable escape of SARS-CoV-2 Omicron to antibody neutralization
Delphine Planas et al.
NATURE (2022)
A two-dose optimum for recombinant S1 protein-based COVID-19 vaccination
Zhidong Hu et al.
VIROLOGY (2022)
Defining the risk of SARS-CoV-2 variants on immune protection
Marciela M. DeGrace et al.
NATURE (2022)
RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge
Juan Shi et al.
TRANSLATIONAL RESEARCH (2022)
A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection
Juan Shi et al.
JOURNAL OF VIROLOGY (2022)
Effective vaccination strategy using SARS-CoV-2 spike cocktail against Omicron and other variants of concern
Juan Shi et al.
NPJ VACCINES (2022)
Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission
Lok Bahadur Shrestha et al.
REVIEWS IN MEDICAL VIROLOGY (2022)
mRNA vaccines elicit potent neutralization against multiple SARS-CoV-2 omicron subvariants and other variants of concern
Gang Wang et al.
ISCIENCE (2022)
Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates
Yin-Feng Kang et al.
ACS NANO (2021)
Receptor-Binding Domain Proteins of SARS-CoV-2 Variants Elicited Robust Antibody Responses Cross-Reacting with Wild-Type and Mutant Viruses in Mice
Juan Shi et al.
VACCINES (2021)
Adjuvanting a subunit COVID-19 vaccine to induce protective immunity
Prabhu S. Arunachalam et al.
NATURE (2021)
A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2
Wanbo Tai et al.
CELL RESEARCH (2020)
The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2
Shibi Muralidar et al.
BIOCHIMIE (2020)
Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial
Carolina Porras et al.
LANCET ONCOLOGY (2020)
Could imiquimod (Aldara 5% cream) or other TLR7 agonists be used in the treatment of COVID-19?
Huseyin Avcilar et al.
MEDICAL HYPOTHESES (2020)
A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years
Tino F. Schwarz et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2019)
Effects of Adjuvants on the Immunogenicity and Efficacy of a Zika Virus Envelope Domain III Subunit Vaccine
Xinyi Wang et al.
VACCINES (2019)
Co-stimulation With TLR7 Agonist Imiquimod and Inactivated Influenza Virus Particles Promotes Mouse B Cell Activation, Differentiation, and Accelerated Antigen Specific Antibody Production
Can Li et al.
FRONTIERS IN IMMUNOLOGY (2018)
Recombinant Hepatitis B Vaccine Adjuvanted With AS04 in Dialysis Patients: A Prospective Cohort Study
Fabrizio Fabrizi et al.
KIDNEY & BLOOD PRESSURE RESEARCH (2015)
Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial
H. Tinto et al.
LANCET (2015)
The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect
Samuele Calabro et al.
VACCINE (2013)
Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice
Najoua Dendouga et al.
VACCINE (2012)
Development of an AS04-Adjuvanted HPV Vaccine with the Adjuvant System Approach
Nathalie Garcon et al.
BIODRUGS (2011)
Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential
MA Stanley
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2002)
Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway
H Hemmi et al.
NATURE IMMUNOLOGY (2002)